Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sir Richard Sykes stated we want to lead in this process not be carried along by it as Glaxo sought to address the looming expiry of its blockbuster Zantac…
The $14 billion cash and stock offer was 49% higher than closing price of Wellcome shares and seemed designed to discourage any competing bids according to…
The FTC reviewed the proposed merger of Glaxo plc and Wellcome plc, addressing competitive concerns in the market for anti-migraine and anti-emetic drugs.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Glaxo acquired Wellcome plc for approximately £9 billion (~$14.2B), creating Glaxo Wellcome plc, then the world's largest pharmaceutical company. The deal was driven by Glaxo's need to diversify beyond Zantac as its patent expiry loomed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Glaxo plc / Wellcome plc (this deal) | 1995 | $14.2B | 61 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 1995 deals · Infectious Disease deals